P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY

Podobne knjige/članki

• Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
  od: Yian Zhang, et al.
  Izdano: (2025-08-01)
• First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial
  od: Xue Yang, et al.
  Izdano: (2026-04-01)
• Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
  od: Abdur Raqib M, et al.
  Izdano: (2023-10-01)
• Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
  od: Natsumi Kawasaki, et al.
  Izdano: (2025-10-01)
• Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma
  od: Yoshikazu Hori, et al.
  Izdano: (2024-01-01)